India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
In a major reform aimed at improving the ease of doing business in India, the…
José Antonio Kast has officially taken office as the new President of Chile, marking a…
Child marriage is a serious social issue in India, affecting the rights, health, and education…
Prime Minister Narendra Modi recently dedicated a modern elevated road corridor connecting Pandu Port to…
The Union Ministry of Jal Shakti is taking big steps under Jal Jeevan Mission (JJM)…
The Ministry of Housing & Urban Affairs (MoHUA) hosted the AMRUT Mitra Mahotsav 2026 at…